Feb 8 |
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
|
Jan 22 |
With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors
|
Jan 8 |
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
|
Jan 3 |
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
|
Jan 2 |
Athira Pharma 10% owner Perceptive Advisors discloses purchase of 605,686 shares
|
Jan 2 |
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
|
Dec 26 |
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
|
Dec 12 |
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
|
Dec 5 |
Sidoti Events, LLC's Virtual December Small-Cap Conference
|
Nov 15 |
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
|